Drug Profile
Research programme: Oragens - AIM ImmunoTech
Alternative Names: Oragens; OragenTM0004Latest Information Update: 05 Sep 2019
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer AIM ImmunoTech
- Class Adenine nucleotides; Oligonucleotides
- Mechanism of Action Hepatitis B virus replication inhibitors; HIV replication inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; HIV infections; Solid tumours; Viral infections
Most Recent Events
- 23 Aug 2019 Hemispherx Biopharma is now called AIM Immunotech
- 19 Aug 2005 This programme is still in active development
- 18 Sep 2003 Preclinical trials in Hepatitis B in USA (PO)